Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

• June 24, 2026

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

• by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

• September 17, 2026

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

• by Henry Noren, Gabriella Pelofsky, Brianna Suffren, Laura Mittelman, Christine Yohn, Aminah Twyman, Christopher A. Febres-Aldana, Arevik Abramyan, Aparna Sertil, Randy S. D’Amico, Jonathan H. Sherman, Morana Vojnic

• September 16, 2026

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min